Loading...
•
Dec 31, 2020
Eton Q4 2020 Earnings Report
Eton reported Q4 2020 financial results, marked by the commercial launch of ALKINDI SPRINKLE and strategic moves to enhance profitability.
Key Takeaways
Eton Pharmaceuticals reported $0.1 million in revenue for Q4 2020, with a net loss of $7.7 million. The company launched ALKINDI SPRINKLE late in the quarter, and its impact on revenue was minimal. The company is focusing on achieving profitability by the end of 2021.
ALKINDI SPRINKLE was launched in late 2020, with promotional activities accelerating in 2021.
Eton acquired Canadian rights to ALKINDI SPRINKLE in January 2021.
The company sold its neurology oral liquid products to Azurity Pharmaceuticals for up to $45 million plus royalties.
R&D expenses for Q4 2020 were $3.4 million, including a $1.4 million FDA filing fee for topiramate.
Forward Guidance
Eton expects to report more than $25 million of revenue in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...